1 Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710; and 2 Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Surfactant protein A (SP-A), a pulmonary lectin, plays an important role in regulating innate immune cell function. Besides accelerating pathogen clearance by pulmonary phagocytes, SP-A also stimulates alveolar macrophage chemotaxis and directed actin polymerization. We hypothesized that SP-A would also stimulate neutrophil chemotaxis. With the use of a Boyden chamber assay, we found that SP-A (0.5-25 µg/ml) did not stimulate chemotaxis of rat peripheral neutrophils or inflammatory bronchoalveolar lavage (BAL) neutrophils isolated from LPS-treated lungs. However, SP-A affected neutrophil chemotaxis toward the bacterial peptide formyl-met-leu-phe (fMLP). Surprisingly, the effect was different for the two neutrophil populations: SP-A reduced peripheral neutrophil chemotaxis toward fMLP (49 ± 5% fMLP alone) and enhanced inflammatory BAL neutrophil chemotaxis (277 ± 48% fMLP alone). This differential effect was not seen for the homologous proteins mannose binding lectin and complement protein 1q but was recapitulated by type IV collagen. SP-A bound both neutrophil populations comparably and did not alter formyl peptide binding. These data support a role for SP-A in regulating neutrophil migration in pulmonary tissue.
lung; formyl-met-leu-phe; collectin; inflammation
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
AT THE INITIATION of inflammation, neutrophils are recruited from the bloodstream into extravascular tissue. The presence of an inflammatory stimulus in the tissue, such as bacteria or bacterial LPS, results in the localized generation of cytokines, leukotrienes, and other proinflammatory mediators that enter the vasculature and stimulate the surrounding tissue, causing changes in surface molecule expression and potentiation of proinflammatory mediator production. Circulating neutrophils respond to these stimuli by altering surface molecule expression resulting in neutrophil adhesion to the surrounding vascular endothelium. Gradients of proinflammatory signals then stimulate the migration of these neutrophils across the vascular endothelium and into the adjacent infected tissue (reviewed in Refs. 20, 21).
The directed migration or chemotaxis of neutrophils is essential to execution of an inflammatory response. A variety of molecules are known to stimulate neutrophil chemotaxis (7). These include microbial products such as the bacterial peptide formyl met-leu-phe (fMLP), activated complement (C5a), cytokines such as IL-8 and macrophage inhibitory protein 2 (MIP-2), and bioactive lipids such as leukotriene B4. All of these chemoattractants bind G protein-coupled receptors on the surface of neutrophils. Ligand binding of these receptors stimulates signaling events that result in cytoskeletal rearrangements and cell migration.
Surfactant protein A (SP-A) is a large multimeric protein found in the
airways and alveoli of the lungs. SP-A is a member of the collectin
protein family that is characterized by NH2-terminal collagen-like domains and COOH-terminal lectin, or carbohydrate-binding domains. These proteins are innate immune molecules, and
SP-A's best-characterized immunoregulatory interaction is
with the resident pulmonary phagocyte, the alveolar macrophage
(30). SP-A stimulates a variety of macrophage responses
such as chemotaxis, actin polymerization, and phagocytosis (25,
30, 31). SP-A also regulates responses involved in the
initiation and potentiation of inflammation by decreasing
proinflammatory tumor necrosis factor- production in response to LPS
(14) and by accelerating the clearance of apoptotic
neutrophils during the resolution of inflammation (17). In
this way, SP-A is believed to help protect the delicate pulmonary tissue from potentially damaging effects of inflammation. Studies with
mice made deficient for SP-A by homologous recombination support this
hypothesis; these mice show a decreased ability to clear a pulmonary
bacterial challenge and a large and persistent pulmonary infiltration
of neutrophils (12).
In this study, we investigated the ability of SP-A to regulate neutrophil chemotaxis and found that although SP-A did not directly stimulate chemotaxis, it did regulate neutrophil chemotaxis toward known chemoattractants. This regulation was, however, dependent on the activation state of the neutrophil; peripheral neutrophils showed decreased chemotaxis in the presence of SP-A, and neutrophils isolated from inflamed lungs showed increased chemotaxis in the presence of SP-A. We examined the ability of homologous proteins to mediate neutrophil chemotaxis and explored the mechanism by which SP-A is differentially regulating the migration of the two different neutrophil populations. This study provides evidence that SP-A indeed regulates neutrophil migration most likely via its collagen-like domain through some internal regulatory mechanism that remains to be identified.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Reagents. Hetastarch was produced by Abbott Laboratories (North Chicago, IL). DPBS, Gey's balanced salt solution (GBSS), and HBSS were obtained from Gibco Laboratories (Grand Island, NY). Iodo-Beads, desalting gel columns, and bicinchoninic acid protein assays were all obtained from Pierce (Rockford, IL). Na125I was purchased from DuPont-NEN (Boston, MA). Human serum C1q was purchased from Advanced Research Technologies (San Diego, CA). IgG purified from normal rat serum was purchased from Sigma Chemical (St. Louis, MO). The IgG was reconstituted from lyophilized powder in saline and used without further treatment. All other chemicals used were from Sigma Chemical, unless otherwise indicated.
Animals. Male Sprague-Dawley rats weighing ~200-400 g were obtained from Charles River (Raleigh, NC) or Taconic Farms (Germantown, NY).
Protein purification.
SP-A was purified from the bronchoalveolar lavage (BAL) fluid of
patients with alveolar proteinosis as previously described (14). Briefly, SP-A was extracted from lavage fluid with
butanol and sequential solubilization in octylglucoside and 5 mM Tris, pH 7.4. The SP-A was treated with polymyxin B agarose beads to reduce
endotoxin contamination. All SP-A preparations had <0.1 pg
endotoxin/µg SP-A by the Limulus amebocyte lysate
assay QCL-1000 (BioWhittaker, Walkersville, MD). SP-A was stored in 5 mM Tris, pH 7.4, at 20°C. Heat treatment of SP-A was carried out at
95°C for 10 min.
Iodination of SP-A. Purified SP-A was iodinated using N-chloro-benzenesulfonamide oxidizing agent immobilized on Pierce Iodo-Beads (26). Free Na125I was separated from 125I-labeled protein on D-salt exocellulose GF-5 desalting gel columns. Fractions that contained radioactivity that was >85% precipitable by trichloroacetic acid were analyzed for protein concentrations by bicinchoninic acid protein assay and stored at 4°C. Radiolabeled SP-A was used within 2 wk.
Neutrophil isolation. Peripheral neutrophils were isolated as previously described with minor modifications (23, 29). Briefly, rats were anesthetized by intramuscular injection of 0.1 mg acepromazine, 7 mg ketamine, and 29 mg xylazine per 250 g body wt, and the jugular was cannulated with a 23-gauge butterfly needle attached to a three-way stop cock. An exchange of 3-4 ml of 6% hetastarch solution with 100 U/ml heparin for 3-4 ml of blood was performed until 40 ml were exchanged per rat. The first 10 ml of blood were collected in a syringe containing 10 ml of the hetastarch solution. After the exchange, blood was collected until the rats died. Blood was allowed to settle 30-45 min at room temperature, and the red blood cell-depleted fraction was collected and centrifuged at 330 g for 10 min. Cells were resuspended in 2 ml of DPBS and underlayed with a five-step Percoll gradient. Step densities were 1.081, 1.085, 1.089, 1.093, and 1.097. Gradients were centrifuged at 500 g for 30 min at room temperature, and the fractions at the interfaces of 1.085-1.089 and 1.089-1.093 density layers were pooled, washed, and resuspended in the appropriate buffer. Neutrophil purities were 83 ± 3% as determined by hematoxylin differential stain (EM Science, Gibbstown, NJ). Other cell types present were 7 ± 1% eosinophils and 10 ± 3% mononuclear cells. Cells were 98 ± 1% viable as determined by trypan blue exclusion.
For isolation of inflammatory BAL neutrophils, rats received an intratracheal instillation of LPS (100 µg of O26:B6/kg rat in 350 µl of normal saline). Twelve hours later, the lungs were lavaged six times with PBS (pH 7.2) containing 0.2 mM EGTA. Cells were collected by centrifuging the BAL fluid for 10 min at 228 g. Cells were then suspended in 2 ml of DPBS per rat and underlayed with the same five-step Percoll gradient used for isolation of peripheral neutrophils. Gradients were centrifuged at 500 g for 30 min at room temperature, and the fractions at the interfaces of 1.085-1.089 and 1.089-1.093 density layers were pooled, washed, and resuspended in the appropriate buffer. Neutrophil purities were >97% as determined by hematoxylin differential stain. Human peripheral neutrophils were isolated from whole blood using Mono-Poly Resolving Medium (ICN Biochemicals, Aurora, OH) according to the manufacturer's specifications. Neutrophils were >95% pure.Chemotaxis assay. Chemotaxis assays were performed using a Neuro Probe 48-well microchemotaxis chamber (Cabin John, MD) (31). Lower wells were filled with the chemotactic test solution diluted in chemotaxis buffer (GBSS + 2% BSA). Poretics polyvinylpyrrolidone-free polycarbonate filters with 2-µm pores (Osmonics, Livermore, CA) were used. The assembly was incubated at 37°C, 5% CO2 for 10 min before cell suspensions (2.5 × 106 cells/ml chemotaxis buffer) were added. After a 30-min incubation at 37°C, 5% CO2, the filter was stained by hematoxylin differential stain and analyzed by light microscopy for the number of cells that had migrated through the filter. Ten randomly selected oil immersion fields were counted at ×100 magnification. Chemotactic stimuli were analyzed in triplicate and averaged for each experiment.
Phagocytosis assay. Fluorescein beads were conjugated with BSA according to the manufacturer's directions in the Polysciences Carbodiimide kit (Warrington, PA). Neutrophils at 106 cells/ml were coincubated 1:10 with BSA-coupled beads in a final assay volume of 0.5 ml PBS + 0.1% BSA. Incubations were carried out in BSA-coated tubes (coated for 1 h at 37°C) for 30 min at 37°C in the presence and absence of 25 µg/ml SP-A. Cells were then washed three times and fixed with 1% formaldehyde before analysis by flow cytometry.
Iodinated SP-A binding assay. To measure binding of iodinated SP-A, neutrophils were suspended at 5 × 106 cells/ml in binding buffer (DPBS with 0.1% BSA and either 0.9 mM CaCl2 + 0.5 mM MgCl2 or 1 mM EDTA as indicated). Assay tubes were precoated with 1% BSA overnight at 4°C. Iodinated SP-A was coincubated with 2 × 106 cells in 0.5 ml of buffer for 4 h at 4°C with gentle rotation. To minimize nonspecific absorption of radioactivity to the tubes, cells were washed once with cold binding buffer lacking BSA and transferred to new tubes. Cells were then washed twice more and lysed (50 mM sodium phosphate buffer, pH 7.2, 150 mM NaCl, 2 mM EDTA, and 0.5% Nonidet P-40). All washes were done at 4°C. Incorporated radioactivity was analyzed by gamma counting, and radioactive signal was normalized to total cellular protein recovered (quantitated by bicinchoninic acid protein assay). Background was determined by performing the assay in the absence of cells and detectable background counts were subtracted from the samples with cells.
Quantitation of fMLP receptor expression. fMLP receptor expression was measured using the fluorescein-conjugated formyl peptide formyl-Nle-Leu-Phe-Nle-Tyr-Lys (Molecular Probes, Eugene, OR) (1). Varying concentrations of peptide (1, 2, 5, 10, and 20 nM) were incubated with 2.5 × 106 neutrophils/ml binding buffer (HBSS + 1% BSA + 0.1% azide) for 30 min on ice. Cells were then washed and resuspended in fixative (1% formaldehyde in DPBS) for analysis by flow cytometry. Cells were analyzed for the mean relative fluorescence as an indication of the relative quantity of formyl peptide bound. For measurement of the effect of SP-A on formyl peptide binding, 25 µg/ml SP-A were added to the binding reaction. For measurement of the effect of SP-A on fMLP receptor expression, cells were incubated in the chemotaxis buffer plus 25 µg/ml SP-A for 30 min at 37°C with gentle shaking. Cells were then washed with DPBS without calcium or magnesium + 1 mM EDTA + 1% BSA and resuspended in binding buffer, and formyl peptide binding was measured as described.
CD11b expression. Neutrophils at 2 × 106 cells/ml HBSS + 0.1% BSA were incubated with FITC-conjugated CD11b (PharMingen, San Diego, CA) for 5 min at 37°C and then stimulated with SP-A (25 µg/ml), fMLP (0.1 mM), or SP-A + fMLP for 10 min at 37°C (3). Cells were immediately washed with 1 ml of cold HBSS + 0.1% BSA and suspended in fixative for analysis by flow cytometry.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
SP-A does not directly stimulate neutrophil chemotaxis.
In contrast to its effects on macrophage chemotaxis, SP-A did not
directly stimulate peripheral or inflammatory BAL neutrophil migration
above buffer alone (GBSS) at a range of concentrations tested
(0.5-25 µg/ml) (Fig. 1). The
bacterial peptide fMLP (10 nM) stimulated chemotaxis, and inflammatory
BAL neutrophils were significantly more responsive to fMLP than
peripheral neutrophils.
|
SP-A regulates neutrophil chemotaxis stimulated by
chemoattractants.
Although SP-A alone did not directly stimulate neutrophil migration, we
analyzed its ability to affect neutrophil migration toward several
different chemoattractants. We measured the effect of 25 µg/ml SP-A
on neutrophil chemotaxis toward MIP-2, activated complement protein C3b
in zymosan-activated serum (ZAS), and fMLP. SP-A significantly altered
both peripheral and inflammatory BAL chemotaxis toward these
chemoattractants. However, the effect was dependent on the activation
state of the neutrophil. SP-A significantly inhibited peripheral
neutrophil chemotaxis toward MIP-2 and fMLP and significantly enhanced
inflammatory BAL chemotaxis toward each chemoattractant tested (Fig.
2). Significant inhibition of peripheral
neutrophil chemotaxis toward ZAS was not observed at the concentration
tested (5% ZAS) (Fig. 2).
|
|
|
SP-A regulates neutrophil phagocytosis.
To explore whether SP-A may regulate another aspect of neutrophil
function, neutrophil phagocytosis was examined. Peripheral and
inflammatory BAL neutrophils were incubated with BSA-conjugated fluorescein beads in the presence and absence of 25 µg/ml SP-A. SP-A
significantly reduced peripheral neutrophil phagocytosis to 70 ± 9% vs. control, whereas SP-A enhanced BAL neutrophil phagocytosis to
143 ± 35% vs. control (Fig.
5). Although enhancement of BAL neutrophil phagocytosis was not statistically significant, SP-A clearly
had different effects on peripheral and BAL neutrophils.
|
Specificity of SP-A's effect on neutrophil chemotaxis.
To determine if SP-A's effect was specific, we examined the ability of
other proteins to regulate neutrophil migration toward fMLP. IgG, which
does not share any structural homology to SP-A but is a soluble
immunoregulatory protein, did not alter peripheral or inflammatory BAL
neutrophil chemotaxis toward fMLP (Table
1). MBL, a serum member of the collectin
protein family, and complement protein C1q both share significant
structural homology to SP-A. In contrast to SP-A, neither MBL nor C1q
(at 25 µg/ml) significantly altered peripheral or inflammatory BAL
neutrophil chemotaxis toward fMLP (Table 1). None of these proteins
alone at 25 µg/ml significantly stimulated neutrophil chemotaxis
(data not shown).
|
|
Binding of SP-A to peripheral vs. inflammatory BAL neutrophils.
Because of the differential effect of SP-A on peripheral and
inflammatory BAL neutrophil chemotaxis, we examined if there was a
difference in binding of SP-A to the two neutrophil populations. Iodinated SP-A at 2, 5, and 10 µg/ml was incubated with the
neutrophils for 4 h at 4°C. There was no apparent difference in
binding of SP-A to peripheral and inflammatory BAL neutrophils (Fig.
6). Higher doses of SP-A were tested, but
background levels of radioactivity (as assessed by radioactivity that
pelleted in the absence of cells) became significant, suggesting that
the iodinated protein was aggregating at concentrations equal to or
greater than 25 µg/ml (data not shown).
|
Effect of SP-A on fMLP receptor expression.
To determine if SP-A's ability to regulate neutrophil chemotaxis is
due to an alteration in fMLP receptor expression, we measured receptor
expression on the peripheral vs. inflammatory BAL neutrophils. Fluorescein-conjugated formyl peptide (formyl-Nle-Leu-Phe-Nle-Tyr-Lys) at 1, 2, 5, 10, and 20 nM was incubated with peripheral and
inflammatory BAL neutrophils for 30 min on ice. Formyl peptide binding
to neutrophils was dose dependent and saturated between 5 and 10 nM
(Fig. 7). As has been reported for
LPS-stimulated peripheral neutrophils (1), we found that
fMLP receptor expression was greater for activated inflammatory BAL
neutrophils than for peripheral neutrophils (Fig. 7). To determine if
the presence of SP-A could alter peptide binding or receptor
expression, we added SP-A to the binding reaction or pretreated the
neutrophils with SP-A under the chemotaxis assay conditions (30 min at
37°C). Neither coincubation of the peptide with SP-A (Fig. 7) nor
pretreatment of the neutrophils with SP-A (data not shown) altered
formyl peptide binding to the peripheral or inflammatory BAL
neutrophils.
|
Effect of SP-A on fMLP-stimulated CD11b levels.
Besides stimulating chemotaxis, fMLP also upregulates CD11b expression
on the neutrophil surface by stimulating release of secondary and
tertiary granules and secretory vesicles where this 2-integrin is stored (4, 10). Consistent
with the literature, we found that fMLP stimulated a significant
increase in CD11b on the surface of peripheral neutrophils (Fig.
8). This was also observed for
inflammatory BAL neutrophils, although the percent increase in levels
was less in the BAL neutrophils than in the peripheral neutrophils
(Fig. 8). This is likely due to the already high basal CD11b levels on
the inflammatory BAL neutrophils (Fig. 8A). SP-A alone had
no effect on levels of CD11b. However, SP-A subtly, yet significantly,
reduced fMLP-stimulated CD11b levels in the peripheral neutrophils
(Fig. 8B). SP-A had no significant effect on fMLP-stimulated
CD11b expression on inflammatory BAL neutrophils.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
These studies describe for the first time SP-A's ability to alter neutrophil responsiveness to chemoattractants. We show that SP-A enhances chemotaxis of inflammatory BAL neutrophils toward fMLP, MIP-2, and ZAS, and SP-A reduces peripheral neutrophil chemotaxis toward fMLP and MIP-2. Because of the inherent limitations of in vitro chemotaxis assays (reviewed in Ref. 28), we also investigated the effects of SP-A on other neutrophil functions, including phagocytosis and expression of CD11b. Although the effects of SP-A were more pronounced for chemotaxis than for other functions, we found that SP-A differentially regulates a variety of peripheral and inflammatory neutrophil functions. These studies suggest that SP-A may play an important role in regulating neutrophil functions in the lung. It was surprising that SP-A did not directly stimulate neutrophil chemotaxis, as has been observed by alveolar macrophages. A comparison of SP-A binding to alveolar macrophages vs. neutrophils (Fig. 6) suggests that neutrophils have one-fifth the number of SP-A binding sites as has been reported for alveolar macrophages (15). This suggests that neutrophils may lack a receptor for SP-A chemotactic stimulation. One study reported the ability of SP-A to stimulate peripheral neutrophil chemotaxis (6). The ability of SP-A to stimulate in their assays may be due to subtle assay differences or differences in SP-A preparations. To rule out the possibility of the lack of effect being due to the species discrepancy between the SP-A and cells used, we also examined whether human SP-A could stimulate human peripheral neutrophil chemotaxis. No chemotaxis was observed at 5 µg/ml (data not shown) or 25 µg/ml SP-A (Fig. 3). The inability of SP-A to directly stimulate chemotaxis is supported by a study that reports that exogenous surfactant is unable to stimulate neutrophil chemotaxis (8). Importantly, it should be noted that the BAL neutrophils have been previously exposed to SP-A. Thus, any regulatory effects or the lack thereof that are a consequence of this exposure cannot be controlled for.
The finding that SP-A differentially regulates peripheral and inflammatory BAL neutrophil chemotaxis toward fMLP, MIP-2, and ZAS is consistent with previous reports that exudated cells differ in many respects from peripheral blood cells (5, 16, 18, 27). The findings are also consistent with previous reports that SP-A has differential effects on activated vs. resting macrophages (9, 22). Neutrophils are rarely found in the alveolar space of the noninflamed lung, but when neutrophils are recruited during inflammation, migration into the alveolar space and in contact with SP-A would give them the capacity to respond more rapidly to chemoattractants that are present during inflammation. A role for SP-A in regulating neutrophil migration is supported by data obtained from studies with SP-A knockout mice, which show that once pulmonary inflammation is initiated, there is a large persistent infiltration of neutrophils into the pulmonary space (12) in the lungs of the knockout mice. However, it is important to note that the increased neutrophil migration in these models may be due to factors other than the absence of SP-A, including differences in cytokine levels and regulation of production of oxidant species.
Extracellular matrix proteins have been reported to affect leukocyte trafficking. Fibrin degradation products have been implicated in stimulating neutrophil chemotaxis, and chemotaxis was enhanced by the presence of LPS (11). Also, collagen has been reported to stimulate neutrophil chemotaxis (19). However, it has been reported that extracellular matrix produced by cultured endothelial cells has no neutrophil chemotactic activity yet did inhibit neutrophil activation by fMLP (13).
It does not seem likely that SP-A is altering chemoattractant interactions at the neutrophil plasma membrane. FITC-formyl peptide Nle-Leu-Phe-Nle-Tyr-Lys is a marker for fMLP receptors (1), and the presence of SP-A did not affect peptide binding (Fig. 7). Also, when neutrophils were pretreated with SP-A under chemotaxis assay conditions and receptor expression was examined, there was no difference in peptide binding (data not shown). All of the attractants tested stimulate neutrophils through G protein-coupled receptors. A phenomenon of these receptors is desensitization. During desensitization, after the ligand binds the receptor, the receptor is internalized, which leads to a reduced ability of the cells to respond to subsequent chemoattractant stimulation (reviewed in Ref. 2). An exciting possible implication of the data reported here is that SP-A may be altering this desensitization process. Future studies may determine if this is the case.
Overall, these studies add to the growing body of data describing SP-A's immunoregulatory role in the pulmonary tissue. These data show that this regulation is not only dependent on the type of leukocyte examined but also the activation state of the leukocyte. The ability of SP-A to differentially regulate different leukocyte populations supports the model that SP-A plays a significant role in tipping the balance of inflammation in favor of the beneficial vs. the damaging effects. In this way, SP-A is helping protect the delicate pulmonary epithelium while facilitating pathogen clearance.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank H. Garner and P. Keating for purifying the SP-A used in these studies. We also thank Dr. T. R. Martin, University of Washington, Seattle, Washington, for helpful discussions and encouragement.
![]() |
FOOTNOTES |
---|
This work was supported by National Heart, Lung, and Blood Institute Grant RO1-HL-51134.
Address for reprint requests and other correspondence: J. R. Wright, Box 3709, Duke Univ. Medical Center, Durham, NC 27710 (E-mail: j.wright{at}cellbio.duke.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
August 30, 2002;10.1152/ajplung.00125.2002
Received 26 April 2002; accepted in final form 27 August 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Allen, C,
Broom M,
and
Chadwick VS.
Flow cytometry analysis of the expression of neutrophil.
J Immunol Methods
149:
159-164,
1992[ISI][Medline].
2.
Ben-Baruch, A,
Michiel DF,
and
Oppenheim JJ.
Signals and receptors involved in recruitment of inflammatory cells.
J Biol Chem
270:
11703-11706,
1995
3.
Betsuyaku, T,
Liu F,
Senior RM,
Haug JS,
Brown EJ,
Jones SL,
Matsushima K,
and
Link DC.
A functional granulocyte colony-stimulating factor receptor is required for normal chemoattractant-induced neutrophil activation.
J Clin Invest
103:
825-832,
1999
4.
Borregaard, N,
Christensen L,
Bejerrum OW,
Birgens HS,
and
Clemmensen I.
Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contains tetranectin and latent alkaline phosphatase.
J Clin Invest
85:
408-416,
1990[ISI][Medline].
5.
Condliffe, AM,
Kitchen E,
and
Chilvers ER.
Neutrophil priming: pathophysiological consequences and underlying mechanisms.
Clin Sci (Colch)
94:
461-471,
1998[ISI][Medline].
6.
Crouch, EC,
Persson A,
Griffin GL,
Chang D,
and
Senior RM.
Interactions of pulmonary surfactant protein D (SP-D) with human blood leukocytes.
Am J Respir Cell Mol Biol
12:
410-415,
1995[Abstract].
7.
Doherty, DE,
Downey GP,
Schwab BR,
Elson E,
and
Worthen GS.
Lipolysaccharide-induced monocyte retention in the lung. Role of monocyte stiffness, actin assembly, and CD18-dependent adherence.
J Immunol
153:
241-255,
1994
8.
Finck, CM,
Hodell MG,
Marx WH,
Paskanik AM,
McGraw DJ,
Lutz CJ,
Gatto LA,
Picone AL,
and
Nieman GF.
Endotoxin-stimulated alveolar macrophage recruitment of neutrophils and modulation with exogenous surfactant.
Crit Care Med
26:
1414-1418,
1998[ISI][Medline].
9.
Hickman-Davis, J,
Gibbs-Erwin J,
Lindsey JR,
and
Matalon S.
Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite.
Proc Natl Acad Sci USA
96:
4953-4958,
1999
10.
Jones, DH,
Schmalstieg FC,
Dempsey K,
Krater SS,
Nannen DD,
Smith CW,
and
Anderson DC.
Subcellular distribution and mobilization of MAC-1 (CD11b/CD18) in neonatal neutrophils.
Blood
75:
488-498,
1990[Abstract].
11.
Leavell, KJ,
Peterson MW,
and
Gross TJ.
The role of fibrin degradation products in neutrophil recruitment to the lung.
Am J Respir Cell Mol Biol
14:
53-60,
1996[Abstract].
12.
LeVine, AM,
Whitsett JA,
Gwozdz J,
Richardson TR,
Fisher JH,
Burhans MS,
and
Korfhagen TR.
Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung.
J Immunol
165:
3934-3940,
2000
13.
Matzner, Y,
Vlodavsky I,
Michaeli RI,
and
Eldor A.
Selective inhibition of neutrophil activation by the subendothelial extracellular matrix: possible role in protection of the vessel wall during diapedesis.
Exp Cell Res
189:
233-240,
1990[ISI][Medline].
14.
McIntosh, JC,
Mervin-Blake S,
Conner E,
and
Wright JR.
Surfactant protein A protects growing cells and reduces TNF- activity from LPS-stimulated macrophages.
Am J Physiol Lung Cell Mol Physiol
271:
L310-L319,
1996
15.
Pison, U,
Wright JR,
and
Hawgood S.
Specific binding of surfactant protein SP-A to rat alveolar macrophages.
Am J Physiol Lung Cell Mol Physiol
262:
L412-L417,
1992
16.
Sato, S,
Ouellet N,
Pelletier I,
Simard M,
Rancourt A,
and
Bergeron MG.
Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia.
J Immunol
168:
1813-1822,
2002
17.
Schagat, TL,
Wofford JA,
and
Wright JR.
Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils.
J Immunol
166:
2727-2733,
2001
18.
Sengelov, H,
Follin P,
Kjeldsen L,
Lollike K,
Dahlgren C,
and
Borregaard N.
Mobilization of granules and secretory vesicles during in vivo exudation of human neutrophils.
J Immunol
154:
4157-4165,
1995
19.
Senior, RM,
Hinek A,
Griffin GL,
Pipoly DJ,
and
Crouch EC.
Neutrophils show chemotaxis to type IV collagen and its 7S domain and contain a 67 kD type IV collagen binding protein with lectin properties.
Am J Respir Cell Mol Biol
1:
479-487,
1989[ISI][Medline].
20.
Sibille, Y,
and
Marchandise FX.
Pulmonary immune cells in health and disease: polymorphonuclear neutrophils.
Eur Respir J
6:
1529-1543,
1993[Abstract].
21.
Sibille, Y,
and
Reynolds HY.
Macrophages and polymorphonuclear neutrophils in lung defense and injury.
Am Rev Respir Dis
141:
471-501,
1990[ISI][Medline].
22.
Stamme, C,
Walsh E,
and
Wright JR.
Surfactant protein A differentially regulates IFN-- and LPS-induced nitrite production by rat alveolar macrophages.
Am J Respir Cell Mol Biol
23:
772-779,
2000
23.
Sugawara, T,
Miyamoto M,
Takayama S,
and
Kato M.
Separation of neutrophils from blood in human and laboratory animals and comparison of the chemotaxis.
J Pharmacol Toxicol Methods
33:
91-100,
1995[ISI][Medline].
24.
Tino, MJ,
and
Wright JR.
Glycoprotein-340 binds surfactant protein-A (SP-A) and stimulates alveolar macrophage migration in an SP-A-independent manner.
Am J Respir Cell Mol Biol
20:
759-768,
1999
25.
Tino, MJ,
and
Wright JR.
Surfactant protein A stimulates actin polymerization in alveolar macrophages but not peripheral blood monocytes (Abstract).
Am J Respir Crit Care Med
153:
A663,
1996.
26.
Tino, MJ,
and
Wright JR.
Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages.
Am J Physiol Lung Cell Mol Physiol
270:
L677-L688,
1996
27.
Wheeler, MA,
Smith SD,
Garcia-Cardena G,
Nathan CF,
Weiss RM,
and
Sessa WC.
Bacterial infection induces nitric oxide synthase in human neutrophils.
J Clin Invest
99:
110-116,
1997
28.
Wilkinson, PC.
Assays of leukocyte locomotion and chemotaxis.
J Immunol Methods
216:
139-153,
1998[ISI][Medline].
29.
Williams, JH,
Moser KM,
Ulich T,
and
Cairo MS.
Harvesting of noncirculating pool of polymorphonuclear leukocytes in rats by hetastartch exchange transfusion (HET): yield and functional assessment.
J Leukoc Biol
42:
455-462,
1987[Abstract].
30.
Wright, JR.
Immunomodulatory functions of surfactant.
Physiol Rev
77:
931-962,
1997
31.
Wright, JR,
and
Youmans DC.
Pulmonary surfactant protein-A stimulates chemotaxis of alveolar macrophage.
Am J Physiol Lung Cell Mol Physiol
264:
L338-L344,
1993